EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.1.1.49 | glucose-6-phosphate dehydrogenase (NADP+) |
artery |
G6PD is more than 2fold higher in pulmonary arteries compared with coronary arteries |
697523 |
1.11.1.12 | phospholipid-hydroperoxide glutathione peroxidase |
artery |
smooth muscle cells |
688464 |
1.13.11.33 | arachidonate 15-lipoxygenase |
artery |
- |
-, 742845 |
1.13.11.52 | indoleamine 2,3-dioxygenase |
artery |
- |
726042 |
1.14.14.18 | heme oxygenase (biliverdin-producing) |
artery |
pulmonary |
684348 |
1.15.1.1 | superoxide dismutase |
artery |
internal mammary arteries |
675625 |
1.17.3.2 | xanthine oxidase |
artery |
- |
684354 |
1.17.4.4 | vitamin-K-epoxide reductase (warfarin-sensitive) |
artery |
mainly in vascular endothelium |
675907 |
1.2.1.3 | aldehyde dehydrogenase (NAD+) |
artery |
- |
697280 |
1.2.1.47 | 4-trimethylammoniobutyraldehyde dehydrogenase |
artery |
- |
743576 |
1.4.3.13 | protein-lysine 6-oxidase |
artery |
highly expressed in vascular lesions |
684889 |
1.6.1.2 | NAD(P)+ transhydrogenase (Re/Si-specific) |
artery |
- |
392595 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
artery |
- |
685976, 710782 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
artery |
coronary artery endothelial cells |
687649 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
artery |
human pulmonary artery endothelial cell, induction of NAD(P)H oxidase by exposure to hyperoxia for 3 h. Pretreatment of cells with the actin-stabilizing agent phallacidin attenuates hyperoxia-induced cortical actin thickening and reactive oxygen species production, whereas cytochalasin D and latrunculin A enhance basal and hyperoxia-induced reactive oxygen species formation. A 3-h hyperoxic exposure enhances the tyrosine phosphorylation of cortactin and interaction between cortactin and subunit p47phox. Transfection of cells with cortactin small interfering RNA or myristoylated cortactin Src homology domain 3 blocking peptide attenuated reactive oxygen species production and the hyperoxia-induced translocation of p47phox to the cell periphery |
687587 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
artery |
in the mesenteric arteries of streptozotocin-induced diabetic apoE-deficient mice the expression of nox4 and gp91phox, ie. nox2 subunits of NADPH oxidase are enhanced as are endothelial nitric oxide synthase mRNA and protein |
686552 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
artery |
porcine coronary artery endothelial cell, PCAEC. Exposure of cells to hypoxia for 2 h followed by 1 h of reoxygenation significantly increases reactive oxygen species formation. Pretreatment with the NADPH oxidase inhibitors, diphenyleneiodonium and apocynin , significantly attenuates hypoxia/reoxygenation-induced reactive oxygen species formation. Exposure of PCAECs to hypoxia/reoxygenation causes a significant increase in serine-threonine kinase Akt and ERK1/2 activation. Exposure of PCAEC spheroids to hypoxia/reoxygenation significantly increases endothelial spheroid sprouting, whereas pharmacological inhibition of NADPH oxidase or genetic deletion of the NADPH oxidase subunit, p47phox (p47phox/), significantly suppresses these changes |
684345 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
artery |
smoking impaires acetylcholine-induced relaxations of carotid arteries, which can be improved by the NAD(P)H oxidase inhibitor apocynin. Both smoking and in vitro cigarette smoke extract exposure significantly increase vascular superoxide anion production |
684343 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
artery |
study on enzyme activity, function, and expression in cerebral and systemic arteries. Superoxide production from enzyme is 10- to 100fold greater in intracranial arteries, basilar and middle cerebral arteries than in aorta, carotid, renal or mesenteric arteries. Isoform Nox4 shows 10fold higher expression in the basilar arteries versus aorta, carotid and mesenteric arteries |
673106 |
1.6.5.2 | NAD(P)H dehydrogenase (quinone) |
artery |
pulmonary arterial endothelial cell. Increase in enzyme protein and activity upon hyperoxia, i.e. exposure to 95% O2 for 48 h |
671220 |
2.1.1.72 | site-specific DNA-methyltransferase (adenine-specific) |
artery |
intercranial artery |
719373 |
2.2.1.2 | transaldolase |
artery |
wall |
486027 |
2.3.1.149 | Platelet-activating factor acetyltransferase |
artery |
detected by immunohistochemistry in the media of mammary arteries |
693520 |
2.3.1.26 | sterol O-acyltransferase |
artery |
- |
486677 |
2.3.1.B41 | protein-long-chain fatty-acyl-lysine deacylase (NAD+) |
artery |
- |
756672 |
2.4.1.224 | glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase |
artery |
- |
736318 |
2.4.1.225 | N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase |
artery |
- |
736318 |
2.4.3.9 | lactosylceramide alpha-2,3-sialyltransferase |
artery |
in atherosclerosis, excessive GM3 is synthesized in atherosclerotic lesions by macrophages and dendritic cells directly within the arterial walls in blood arteries additionally to the GM3 synthesis in blood plasma, the fatty acid compositions of GM3 from blood plasma low density lipoprotein and from atherosclerotic lesions differ |
657703 |
2.4.3.9 | lactosylceramide alpha-2,3-sialyltransferase |
artery |
level of GM3 synthase in membrane-fractions isolated from the atherosclerotic intima are higher compared to those in non-dieased arterial tissue |
657703 |
2.7.1.137 | phosphatidylinositol 3-kinase |
artery |
- |
708145, 708681 |
2.7.1.153 | phosphatidylinositol-4,5-bisphosphate 3-kinase |
artery |
- |
708686 |
2.7.1.91 | sphingosine kinase |
artery |
gracilis muscle resistance artery. Pressure-dependent activation and translocation of isoform Sk1 by ERK1/2 is critically dependent on its serine225 phosphorylation site |
701973 |
2.7.11.10 | IkappaB kinase |
artery |
mesenteric artery |
761776 |
2.7.11.12 | cGMP-dependent protein kinase |
artery |
- |
662462, 702471 |
2.7.11.13 | protein kinase C |
artery |
- |
671952 |
2.7.11.13 | protein kinase C |
artery |
coronary |
660673 |
2.7.11.13 | protein kinase C |
artery |
pulmonary |
660666 |
2.7.11.15 | beta-adrenergic-receptor kinase |
artery |
- |
684355 |
2.7.11.17 | Ca2+/calmodulin-dependent protein kinase |
artery |
- |
722742 |
2.7.11.18 | myosin-light-chain kinase |
artery |
- |
709692 |
2.7.11.18 | myosin-light-chain kinase |
artery |
maximal stimulation-induced in situ myosin light chain kinase activity is upregulated in fetal compared to adult ovine carotid arteries |
684356 |
2.7.11.18 | myosin-light-chain kinase |
artery |
small resistance mesenteric artery |
-, 740289 |
2.7.11.30 | receptor protein serine/threonine kinase |
artery |
- |
705441 |
2.7.11.31 | [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase |
artery |
intrapulmonary smooth muscle |
692195 |
2.7.8.1 | ethanolaminephosphotransferase |
artery |
CEPT1 is elevated in diseased lower extremity arterial intima of individuals with peripheral arterial disease and diabetes |
760955 |
2.7.8.2 | diacylglycerol cholinephosphotransferase |
artery |
CEPT1 is elevated in diseased lower extremity arterial intima of individuals with peripheral arterial disease and diabetes |
760955 |
2.8.2.1 | aryl sulfotransferase |
artery |
pulmonary, endothelial cell |
677196 |
2.8.2.17 | chondroitin 6-sulfotransferase |
artery |
- |
645752 |
2.8.2.33 | N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase |
artery |
- |
674051 |
2.8.2.8 | [heparan sulfate]-glucosamine N-sulfotransferase |
artery |
- |
645926 |
3.1.1.47 | 1-alkyl-2-acetylglycerophosphocholine esterase |
artery |
nonatherogenic mammary artery |
693520 |
3.1.26.10 | ribonuclease IX |
artery |
- |
646297 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
- |
699755, 749533 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
coronary artery smooth muscle |
666160 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
first-order mesenteric resistance artery, high expression of enzyme with predominance of 3-exon-excluded, leucine-zipper negative MYPT 1 isoform |
663585 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
iliac artery, expression of leucine-zipper positive isoform of MYPT 1 predominates in healthy animal |
664610 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
intrapulmonary arterial tissue, enzyme protein increases with age and is highest in adult rat. In contrast, enzyme specific activity is significantly higher in fetal compared with adult tissue |
663593 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
monolayers of pulmonary artery endothelial cells |
665653 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
of tail |
664611 |
3.1.3.53 | [myosin-light-chain] phosphatase |
artery |
pulmonary artery, predominantly expression of 3-exon-out/leucine-zipper positive MYPT 1 isoform |
663585 |
3.1.4.11 | phosphoinositide phospholipase C |
artery |
mesenteric, pulmonary and middle cerebral arteries |
751920 |
3.1.4.17 | 3',5'-cyclic-nucleotide phosphodiesterase |
artery |
PDE 1 vascular expression is increased in arteries from angiotensin II hypertensive rats |
-, 715153 |
3.1.4.3 | phospholipase C |
artery |
intrapulmonary arteries |
731015 |
3.1.4.35 | 3',5'-cyclic-GMP phosphodiesterase |
artery |
in the vasculature, PDE5 is the predominant PDE isoform involved in degrading cGMP |
711925 |
3.1.4.35 | 3',5'-cyclic-GMP phosphodiesterase |
artery |
PDE5 vascular expression is decreased in arteries from angiotensin II hypertensive rats compared to control rats |
-, 715153 |
3.3.2.10 | soluble epoxide hydrolase |
artery |
- |
707303, 707309 |
3.3.2.10 | soluble epoxide hydrolase |
artery |
renal, in the smooth muscle layer of the arterial wall |
660664 |
3.4.11.2 | membrane alanyl aminopeptidase |
artery |
arterial smooth muscle |
683811 |
3.4.14.5 | dipeptidyl-peptidase IV |
artery |
in artery DPIV represents 92% of the total Gly-L-Pro-4-nitroanilide-hydrolyzing activity |
697386 |
3.4.15.1 | peptidyl-dipeptidase A |
artery |
- |
-, 709411, 752444 |
3.4.17.15 | carboxypeptidase A2 |
artery |
mesenteric arterial bed, enzyme is identical with its pancreatic counterpart |
732609 |
3.4.17.23 | angiotensin-converting enzyme 2 |
artery |
non-diseased mammary arteries and atherosclerotic carotid arteries. Total vessel wall expression of ACE and ACE2 is similar during all stages of atherosclerosis. The observed ACE2 protein is enzymatically active and activity is lower in the stable advanced atherosclerotic lesions, compared to early and ruptured atherosclerotic lesions |
693806 |
3.4.21.37 | leukocyte elastase |
artery |
pulmonary artery endothelial cells |
707071 |
3.4.21.39 | chymase |
artery |
gastroepiploic |
81374, 81375 |
3.4.21.39 | chymase |
artery |
gastroepiploic artery |
679291 |
3.4.21.46 | complement factor D |
artery |
PDGF-D is widely expressed in most neointimas in arteries exhibiting the chronic arteriopathy of chronic allograft nephropathy and is only weakly expressed in a small proportion of sclerotic arteries. The neointimal cells expressing PDGF-D are alpha-smooth muscle actin-expressing cells, but not infiltrating macrophages or endothelial cells |
698194 |
3.4.21.6 | coagulation factor Xa |
artery |
middle cerebral |
651191 |
3.4.21.7 | plasmin |
artery |
vessel wall |
717165 |
3.4.21.B1 | hyaluronan-binding serine protease |
artery |
abundant in neointima and in arteriosclerotic carotid arteries, but not in normal arteries. Accumulation in unstable coronary atherosclerotic plaques with elevated RNA expression in patients with acute coronary syndromes |
687108 |
3.4.21.B1 | hyaluronan-binding serine protease |
artery |
FSAP expression in stable and especially unstable coronary atherosclerotic lesions. FSAP mainly in inflammatory regions within the shoulders of the plaque surounding or located within the lipid core that is infiltrated by macrophages. Some FSAP present within fibrotic regions in the cap of the plaque. Tight colocalization of FSAP and uPA-presenting cells in all plaques. Colocalization also with CD11b/CD68. Also present in hypocellular- and lipid rich areas of atherosclerotic plaques in internal mammary arteries, absent from normal non-atherosclerotic arteries |
684801 |
3.4.21.B26 | proprotein convertase 5 |
artery |
- |
675490 |
3.4.22.1 | cathepsin B |
artery |
cerebral arterial walls |
701244 |
3.4.22.B60 | cathepsin L2 |
artery |
- |
-, 753117 |
3.4.24.24 | gelatinase A |
artery |
aged arterial wall, colocalization of activated enzyme and transforming growth factor TGF-beta1. Treatment of young aortic rings with activated enzyme enhances active transforming growth factor TGF-beta-1, collagen, and fibronectin expression to the level of untreated old counterparts |
667356 |
3.4.24.35 | gelatinase B |
artery |
- |
695947 |
3.4.24.79 | pappalysin-1 |
artery |
- |
683504 |
3.4.24.79 | pappalysin-1 |
artery |
coronary |
683969 |
3.4.24.86 | ADAM 17 endopeptidase |
artery |
atherosclerotic plaque |
677450 |
3.4.24.B9 | ADAM9 endopeptidase |
artery |
carotid and femoral arteries, only weak ADAM-9 expression from thyroid artery without atherosclerosis |
710868 |
4.2.1.3 | aconitate hydratase |
artery |
coronary artery endothelial cells |
747827 |
4.4.1.1 | cystathionine gamma-lyase |
artery |
- |
690376, 691828, 693818 |
4.4.1.1 | cystathionine gamma-lyase |
artery |
tail |
707582 |
4.6.1.2 | guanylate cyclase |
artery |
- |
691656 |
4.6.1.2 | guanylate cyclase |
artery |
coronary artery |
748700 |
4.6.1.2 | guanylate cyclase |
artery |
isozymes GC-A |
692548 |
4.6.1.2 | guanylate cyclase |
artery |
pulmonary |
684348, 691656, 692204 |
4.6.1.2 | guanylate cyclase |
artery |
pulmonary, but not aorta |
691541 |
4.6.1.2 | guanylate cyclase |
artery |
pulmonary, cultured model |
690369 |
5.3.1.8 | mannose-6-phosphate isomerase |
artery |
- |
2624 |
5.3.99.4 | prostaglandin-I synthase |
artery |
- |
748544 |